DocWire News Editors

DocwireNews

Peripheral artery disease (PAD) was associated with continuous and linearly increasing risk for venous thromboembolism (VTE) after lower extremity revascularization (LER). Low-dose rivaroxaban plus aspirin significantly reduced this risk compared with aspirin alone, according to data from a prespecified secondary analysis of VOYAGER-PAD presented by Connie N. Hess, MD, an interventional cardiology at The University of Colorado, at the American Heart Association Scientific Sessions 2020.Prior studies have shown that patients with PAD are at risk for arterial thrombosis. VOYAGER-PAD randomly assigned 6,564 patients undergoing LER to rivaroxaban 2.5 mg twice daily or placebo on a background of aspirin 100 mg daily. Clopidogrel was allowed for up to 6 months. The primary endpoint was acute limb ischemia, major amputation for vascular cause, myocardial infarction, ischemia stroke or cardiovascular death.The primary outcome of this secondary analysis was symptomatic VTE with an exploratory outcome of composite acute venous or arterial thrombotic events. The incidence of VTE was 0.42 per 100 patient-years; 66 patients had VTE by efficacy cut-off date. Compared with patients without VTE, those with VTE were older, had higher body weight, more often had renal dysfunction, and lower use of baseline clopidogrel or statin.The cumulative incidence of VTE was 1.7% in the placebo arm compared with 0.8% in the rivaroxaban arm (HR=0.61; 95% CI, 0.37 to 1.00; P=0.047). This translated to a 39% relative risk reduction associated with rivaroxaban.&ldquo;This benefit appears early, persists over time, and is consistent in major subgroups,&rdquo; Dr. Hess said.There was no heterogeneity in the effect of rivaroxaban according to age, weight, renal function, coronary artery disease, baseline clopidogrel and baseline statin use.Looking at the effect of rivaroxaban on the composite endpoint of acute venous and arterial thrombotic events, there was a 25% relative risk reduction associated with rivaroxaban (16.2% vs. 12.2%; HR=0.75; 95% CI, 0.65 to 0.86; P&lt;0.0001).

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Rivaroxaban Plus Aspirin Protects Against Venous, Arterial Thrombotic Events After LER

AHA Scientific Sessions 2020

Peripheral artery disease (PAD) was associated with continuous and linearly increasing risk for venous thromboembolism (VTE) after lower extremity revascularization (LER). ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe